ES2547404T3 - Composición inhibidora de la agregación plaquetaria - Google Patents
Composición inhibidora de la agregación plaquetaria Download PDFInfo
- Publication number
- ES2547404T3 ES2547404T3 ES09153422.2T ES09153422T ES2547404T3 ES 2547404 T3 ES2547404 T3 ES 2547404T3 ES 09153422 T ES09153422 T ES 09153422T ES 2547404 T3 ES2547404 T3 ES 2547404T3
- Authority
- ES
- Spain
- Prior art keywords
- platelet aggregation
- amino acid
- polypeptide
- acid sequence
- inhibitory activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 title 1
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 title 1
- 229940127218 antiplatelet drug Drugs 0.000 title 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract description 8
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 8
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 8
- 125000003275 alpha amino acid group Chemical group 0.000 abstract description 7
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 description 10
- 108091033319 polynucleotide Proteins 0.000 description 8
- 102000040430 polynucleotide Human genes 0.000 description 8
- 239000002157 polynucleotide Substances 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000003449 preventive effect Effects 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 206010008088 Cerebral artery embolism Diseases 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010060840 Ischaemic cerebral infarction Diseases 0.000 description 2
- 208000006193 Pulmonary infarction Diseases 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 206010047249 Venous thrombosis Diseases 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 208000021328 arterial occlusion Diseases 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 201000010849 intracranial embolism Diseases 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 208000002815 pulmonary hypertension Diseases 0.000 description 2
- 230000007575 pulmonary infarction Effects 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Insects & Arthropods (AREA)
- General Physics & Mathematics (AREA)
Abstract
Composición farmacéutica para su utilización como un medicamento que comprende por lo menos un polipéptido de los (a) a (b) siguientes como un componente activo: (a) un polipéptido que comprende la secuencia de aminoácidos de SEC ID nº: 3; y (b) un polipéptido que comprende una secuencia de aminoácidos que presenta una homología de 70% o superior respecto a la secuencia de aminoácidos del (a) anterior y que presenta una actividad inhibitoria de la agregación plaquetaria y/o una actividad inhibitoria de la adhesión plaquetaria.
Description
5
10
15
20
25
30
35
40
45
50
55
60
65 E09153422
16-09-2015
De acuerdo con esto, SY-001, que posee la actividad inhibitoria sobre la agregación plaquetaria y/o la actividad inhibitoria sobre la adhesión plaquetaria, se cree que tiene la posibilidad de ser útil como el agente terapéutico o el preventivo para los estados patológicos subsiguientes a las enfermedades y sus complicaciones, por ejemplo, infarto miocárdico, embolismo cerebral, obstrucción arterial crónica, esclerosis arterial, infarto cerebral isquémico, angina, trombosis venosa, hipertensión, hipertensión pulmonar, infarto cerebral, infarto pulmonar, fallo cardíaco, nefritis, fallo renal y hemorragia subaracnoidea, causadas por la formación de trombos o émbolos.
El SY-001, que presenta la actividad inhibitoria sobre la agregación plaquetaria y/o la actividad inhibitoria sobre la adhesión plaquetaria, se cree que tiene también la posibilidad de ser útil para prevenir la formación de trombos sobre PTCA y el emplazamiento de las endoprótesis vasculares, y como agente preventivo de la restenosis después de situar la endoprótesis vascular envolviendo el medicamento que contiene SY-001, y aplicándolo sobre o integrándolo en la endoprótesis vascular misma.
No están particularmente limitados el grado y la posición de la modificación de los residuos aminoácidos en SY-001, representados como los anteriores (b) y (d), siempre que el polipéptido (o su equivalente) que incluye la secuencia de aminoácidos modificada posea sustancialmente idéntica actividad que la del polipéptido que incluye la secuencia de aminoácidos de SEC ID nº: 3. Resulta preferido que la anterior modificación se lleve a cabo típicamente con aproximadamente, como a varios residuos aminoácidos.
En la presente invención, las “deleciones, inserciones, sustituciones o adiciones de múltiples aminoácidos”, se refieren a que 2 o más y 20 o menos aminoácidos se han eliminado, insertado, sustituido o añadido. Los aminoácidos múltiples son preferentemente 2 o más y 10 o menos, más preferentemente 2 o más y 7 o menos, y, todavía más preferentemente, 2 o más y 5 o menos. Esta secuencia de aminoácidos modificada posee una homología del 70% o más, preferentemente de aproximadamente 80% o más, más preferentemente de aproximadamente 95% o más, y más preferentemente todavía de aproximadamente 98% o más, con respecto a la secuencia de aminoácidos de SEC ID nº: 3.
Los ejemplos específicos del polipéptido (SY-001) que es el componente activo de la composición farmacéutica de esta invención, son tal como se muestran en los Ejemplos que se describen a continuación.
El SY-001 posee la actividad inhibitoria de una inherente agregación plaquetaria y/o la actividad inhibitoria de la adhesión plaquetaria.
El SY-001 presenta también la capacidad inherente de unión al colágeno.
Por tanto, la composición farmacéutica de la presente invención que contiene SY-001 como componente activo, es útil como agente terapéutico o preventivo de estados patológicos subsiguientes a las enfermedades y sus complicaciones, por ejemplo, síndrome coronario agudo, infarto miocárdico, embolismo cerebral, obstrucción arterial crónica, esclerosis arterial, infarto cerebral isquémico, angina, trombosis venosa, hipertensión, hipertensión pulmonar, infarto cerebral, infarto pulmonar, insuficiencia cardiaca, nefritis, fallo renal y hemorragia subaracnoidea, causados por la formación de trombos o émbolos. La composición farmacéutica de la presente invención también es útil para la prevención de la formación de trombos después del emplazamiento PTCA y de la endoprótesis vascular y como agente preventivo de la reestenosis después de situar la endoprótesis aplicándola sobre ella misma.
(2) Polinucleótido (molécula de ADN) que codifica SY-001.
Una muestra específica del polinucleótido que codifica SY-001 (al que a veces se hace referencia como “una molécula de ADN de SY-001), puede incluir el polinucleótido (molécula de ADN) que comprende la secuencia ADN de SEC ID nº: 4 o su complemento.
Otro ejemplo de la molécula de ADN de SY-001 incluye el polinucleótido que hibrida con el polinucleótido que incluye el complemento para la secuencia de ADN de SEC ID nº: 4 bajo la condición rigurosa y que puede expresar el polipéptido que posee la actividad inhibitoria de la agregación plaquetaria y/o la actividad inhibitoria de la adhesión plaquetaria.
La “condición rigurosa” en la presente memoria puede incluir aquélla en que tiene lugar la hibridización en 2 x SSC que contiene SDS al 0,1% a 50ºC y no está separado lavando en 1 x SSC al 0,1% a 60ºC.
Además, otro ejemplo de la molécula de ADN (polinucleótido) de SY-001 incluye el polinucleótido que comprende la secuencia de ADN que posee una homología del 80% o más, preferentemente el 95% o más, y más preferentemente de aproximadamente 98% o más con respecto a la más estrechamente relacionada entre los polinucleótidos que comprenden la secuencia de ADN de SEC ID nº: 4 o su complemento y que es capaz de expresar el polipéptido que posee la actividad inhibitoria de la agregación plaquetaria y/o la actividad inhibitoria de la adhesión plaquetaria.
9
Claims (1)
-
imagen1 imagen2
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005320817 | 2005-11-04 | ||
| JP2005320817 | 2005-11-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2547404T3 true ES2547404T3 (es) | 2015-10-06 |
Family
ID=38005983
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES06832470.6T Active ES2547380T3 (es) | 2005-11-04 | 2006-11-02 | Composición inhibidora de la agregación plaquetaria |
| ES09153422.2T Active ES2547404T3 (es) | 2005-11-04 | 2006-11-02 | Composición inhibidora de la agregación plaquetaria |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES06832470.6T Active ES2547380T3 (es) | 2005-11-04 | 2006-11-02 | Composición inhibidora de la agregación plaquetaria |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US8034763B2 (es) |
| EP (2) | EP2077328B1 (es) |
| JP (1) | JP4954204B2 (es) |
| KR (1) | KR101311570B1 (es) |
| CN (2) | CN102911264B (es) |
| AR (1) | AR057858A1 (es) |
| AU (1) | AU2006309543B2 (es) |
| BR (1) | BRPI0618194A2 (es) |
| CA (1) | CA2625106C (es) |
| ES (2) | ES2547380T3 (es) |
| IL (2) | IL188986A0 (es) |
| MY (1) | MY148135A (es) |
| PH (1) | PH12013502021B1 (es) |
| RU (2) | RU2434941C2 (es) |
| SG (1) | SG166817A1 (es) |
| TW (1) | TWI391143B (es) |
| WO (1) | WO2007052841A1 (es) |
| ZA (1) | ZA200801161B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108503692B (zh) * | 2017-07-10 | 2019-12-31 | 昆明医科大学第一附属医院 | 一种促血小板聚集的多肽pep1 |
| CN108503689B (zh) * | 2017-07-10 | 2019-12-31 | 昆明医科大学第一附属医院 | 一种抗血小板聚集的多肽km6 |
| CN110339344B (zh) * | 2019-08-07 | 2022-12-30 | 上海交通大学医学院附属仁济医院 | 核受体Rev-erbα在制备抗血小板药物中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0662088T3 (da) * | 1993-07-01 | 2002-02-25 | Merck Patent Gmbh | Inhibitor af kollagen-stimuleret blodpladeaggregering |
| JPH10505502A (ja) | 1994-09-12 | 1998-06-02 | シェーリング アクチェンゲゼルシャフト | 修飾されたコラーゲン誘導血小板凝集阻害剤パリジピンの製法 |
| RU2192857C1 (ru) * | 2001-04-24 | 2002-11-20 | Институт органической химии им. Н.Д. Зелинского РАН | Ингибитор агрегации тромбоцитов, обладающий антиметастатическим действием |
| JP3648548B2 (ja) * | 2001-10-15 | 2005-05-18 | 国立大学法人三重大学 | 血液凝固阻害活性を有するハマダラカ由来のＡｓ−１蛋白質 |
| JP3837519B2 (ja) | 2002-10-02 | 2006-10-25 | 国立大学法人三重大学 | 血小板凝集阻害活性を有するブラジルサシガメ由来のＴｉ−３蛋白質 |
| JP3837518B2 (ja) | 2002-10-02 | 2006-10-25 | 国立大学法人三重大学 | 血小板凝集阻害活性を有するブラジルサシガメ由来のＴｉ−４蛋白質 |
-
2006
- 2006-10-26 TW TW95139546A patent/TWI391143B/zh not_active IP Right Cessation
- 2006-11-02 RU RU2008122338/10A patent/RU2434941C2/ru not_active IP Right Cessation
- 2006-11-02 ES ES06832470.6T patent/ES2547380T3/es active Active
- 2006-11-02 MY MYPI20080355 patent/MY148135A/en unknown
- 2006-11-02 AU AU2006309543A patent/AU2006309543B2/en not_active Ceased
- 2006-11-02 BR BRPI0618194-5A patent/BRPI0618194A2/pt not_active IP Right Cessation
- 2006-11-02 EP EP09153422.2A patent/EP2077328B1/en not_active Not-in-force
- 2006-11-02 ZA ZA200801161A patent/ZA200801161B/xx unknown
- 2006-11-02 CA CA2625106A patent/CA2625106C/en not_active Expired - Fee Related
- 2006-11-02 EP EP06832470.6A patent/EP1943337B1/en not_active Not-in-force
- 2006-11-02 US US12/065,701 patent/US8034763B2/en not_active Expired - Fee Related
- 2006-11-02 CN CN201210390650.2A patent/CN102911264B/zh not_active Expired - Fee Related
- 2006-11-02 RU RU2011120138/10A patent/RU2557296C2/ru not_active IP Right Cessation
- 2006-11-02 CN CN2006800352979A patent/CN101273128B/zh not_active Expired - Fee Related
- 2006-11-02 WO PCT/JP2006/322417 patent/WO2007052841A1/en not_active Ceased
- 2006-11-02 KR KR1020087013445A patent/KR101311570B1/ko not_active Expired - Fee Related
- 2006-11-02 ES ES09153422.2T patent/ES2547404T3/es active Active
- 2006-11-02 SG SG201008077-8A patent/SG166817A1/en unknown
- 2006-11-02 JP JP2008519765A patent/JP4954204B2/ja not_active Expired - Fee Related
- 2006-11-03 AR ARP060104826A patent/AR057858A1/es unknown
-
2008
- 2008-01-24 IL IL188986A patent/IL188986A0/en unknown
-
2011
- 2011-08-22 US US13/215,004 patent/US8309512B2/en not_active Expired - Fee Related
-
2013
- 2013-09-27 PH PH12013502021A patent/PH12013502021B1/en unknown
- 2013-10-21 IL IL228986A patent/IL228986A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Purcell et al. | Delivery of a matrix metalloproteinase-responsive hydrogel releasing TIMP-3 after myocardial infarction: effects on left ventricular remodeling | |
| Standeven et al. | The molecular physiology and pathology of fibrin structure/function | |
| US20060019896A1 (en) | Netrin-related compositions and uses | |
| Caulfield et al. | Structure and function of myocardial fibrillar collagen | |
| HU216318B (hu) | Eljárás a vérlemezkék aggregálódását gátló szerek, és az előállításukhoz alkalmas DNS-szekvenciák, vektorok és gazdasejtek előállítására | |
| JP2018515101A5 (es) | ||
| EP1940445B1 (en) | Stem cell derived paracrine factor h12 for use in reducing cell death or enhancing tissue repair | |
| Lee et al. | Physiology, pharmacology, and therapeutic potential of protease-activated receptors in vascular disease | |
| ES2547404T3 (es) | Composición inhibidora de la agregación plaquetaria | |
| Kalluri | Discovery of type IV collagen non-collagenous domains as novel integrin ligands and endogenous inhibitors of angiogenesis | |
| KR100465222B1 (ko) | 평활근세포증식억제활성을갖는조직인자응고계인히비터(tfpi)-유래펩티드 | |
| JPH06502407A (ja) | 血小板凝集阻害剤 | |
| Osborne-Pellegrin et al. | Changes in aortic stiffness related to elastic fiber network anomalies in the Brown Norway rat during maturation and aging | |
| EP2845601B1 (en) | Composition for use for dissolving thrombi | |
| Hirata et al. | Roles of platelet-activating factor, thromboxane A2, ADP and thrombin in thrombogenesis in the guinea pig | |
| JP2017508806A5 (es) | ||
| US10335449B2 (en) | Rho associated kinase (ROCK) inhibitors and their use in treating disease | |
| Su et al. | Vitronectin | |
| US11202854B2 (en) | Disintegrin variants and uses thereof | |
| McCleary et al. | Reptile venoms as a platform for drug development | |
| van Heel | Distally lobed integuments in some angiosperm ovules | |
| Vanhoorelbeke et al. | The role of VWF-collagen interaction in acute platelet thrombus formation | |
| US20150299264A1 (en) | Inhibition of cardiac fibrosis in myocardial infarction | |
| Begić et al. | Postprocedural dual anticoagulant and antiplatelet treatment after peripheral artery disease endovascular interventions: a shifting paradigm. | |
| MX2007009115A (es) | Metodos y composiciones para reducir el dano microvascular derivado por isquemia. |